Brind.

Samsung Bioepis secures 10-year deal for Soliris biosimilar in Brazil

1 report, 1 independent Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Samsung Bioepis secured a decade-long exclusive supply deal to provide SB12, a biosimilar of Soliris, to Brazil’s Ministry of Health. SB12 is used to treat rare conditions, including paroxysmal nocturnal hemoglobinuria. The agreement involves Samsung Bioepis working with Bionovis and Bahiafarma to supply the medicine and transfer technology to local partners. The drug was approved by Brazil’s health regulator, ANVISA, in December 2024.

From koreatimes.co.kr

Why it matters

Some supportBrind's analysis of the reports

The deal strengthens Samsung Bioepis’ position in the Brazilian pharmaceutical market, which was valued at about $170 million last year for eculizumab treatments. The 10-year agreement is expected to provide a stable source of revenue for the company.

From koreatimes.co.kr

Who's involved

  • SolirisOriginal drug manufacturer whose biosimilar is being supplied.
  • Ministry of HealthBrazilian government organization receiving the supply of the biosimilar.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped